Q4 2024 · 13F-HR
Bain Capital Life Sciences Investors, LLCholdings as filed
Filed 2025-02-14 · accession 0000950123-25-002317
$850.1M
Reported value
26
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $275.5M | 32.4% | 10,719,110 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $113.3M | 13.3% | 1,447,267 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $63.3M | 7.45% | 3,303,381 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $62.4M | 7.33% | 983,500 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $58.6M | 6.90% | 2,689,707 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $44.7M | 5.26% | 14,565,457 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $43.6M | 5.12% | 7,470,214 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $37.7M | 4.44% | 2,295,322 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $26.9M | 3.17% | 5,249,069 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $18.9M | 2.22% | 703,080 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $16.1M | 1.90% | 4,034,582 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $12.6M | 1.48% | 3,368,370 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $12.4M | 1.46% | 16,915,784 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $12.4M | 1.46% | 8,663,673 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $8.4M | 0.99% | 2,712,008 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $8.3M | 0.98% | 2,485,638 | Common | SOLE |
| 75340L104 | RPID | RAPID MICRO BIOSYSTEMS INC | $7.6M | 0.89% | 8,434,560 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $6.3M | 0.74% | 2,760,888 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $5.5M | 0.64% | 5,410,361 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $4.4M | 0.51% | 4,566,817 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $4.0M | 0.47% | 1,111,910 | Common | SOLE |
| 63909J108 | NAUT | NAUTILUS BIOTECHNOLOGY INC | $3.0M | 0.35% | 1,759,000 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $1.4M | 0.17% | 2,693,380 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $1.4M | 0.17% | 100,000 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $797,401 | 0.09% | 1,799,595 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $631,985 | 0.07% | 2,750,151 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.